What are the long-term risks of continuing ciclosporin in this patient beyond

Long-term Risks of Continuing Ciclosporin Therapy Beyond One Year

Continuing ciclosporin therapy beyond one year in this patient carries several notable long-term risks primarily related to its dose-dependent toxicity and immunosuppressive effects. Key concerns include:

• Renal Dysfunction: Ciclosporin is well known to induce renal dysfunction, a principal adverse effect that can become more pronounced with prolonged treatment duration and cumulative dose exposure. This nephrotoxicity may manifest as chronic kidney injury requiring close renal function monitoring SmPC Capsorin,SmPC SANDIMMUN,SmPC Neoral,SmPC Neoral.
• Hypertension and Metabolic Disturbances: Long-term use commonly results in hypertension and metabolic abnormalities such as hyperlipidaemia, hyperglycaemia, hyperuricaemia, hyperkalaemia, and hypomagnesaemia, all contributing to cardiovascular risk burden and complicating management SmPC Capsorin,SmPC SANDIMMUN,SmPC Neoral,SmPC Neoral.
• Increased Risk of Infections: As an immunosuppressant, ciclosporin heightens susceptibility to viral, bacterial, fungal, and parasitic infections, including reactivation of latent viruses and more frequent localized or systemic infections. The patient’s experience of mouth ulcers and cold sores aligns with such risks and underscores the need for vigilance SmPC Capsorin,SmPC SANDIMMUN,SmPC Neoral,SmPC Neoral.
• Cumulative Malignancy Risk: Prolonged immunosuppression increases the risk of lymphomas and other malignancies, particularly skin cancers, with risk magnitude rising in proportion to intensity and duration of therapy. This requires careful dermatologic surveillance and cancer screening SmPC Capsorin,SmPC SANDIMMUN,SmPC Neoral,SmPC Neoral,Zengarini et al. 2026,Moroni et al. 2026.
• Neurological and Other Adverse Effects: Potential for tremor, headache, encephalopathy (including posterior reversible encephalopathy syndrome), motor polyneuropathy, and optic disc edema also increase with extended therapy SmPC Capsorin,SmPC SANDIMMUN,SmPC Neoral,SmPC Neoral.

UK guidelines caution against continuous use of ciclosporin beyond 1 year outside of severe or unstable disease due to these risks and the availability of alternative treatments NICE CG153. The typical approach encourages using the lowest effective dose, limiting duration, and prompt consideration of other systemic options or biologics such as dupilumab in atopic eczema NICE CG153.

In clinical practice, the balance between benefits and risks must be individually assessed, especially in younger patients facing lifelong therapy implications. Close monitoring of renal function, blood pressure, lipid profile, blood glucose, and skin examinations is essential SmPC Capsorin,NICE CG153,Zengarini et al. 2026,Moroni et al. 2026. Patient education to report infections and adverse effects early is critical. Dose adjustments or switching immunosuppressive agents may help mitigate toxicity SmPC Capsorin,Moroni et al. 2026.

Overall, the decision to continue ciclosporin beyond one year should involve specialist dermatology and/or immunology input, weighing potential long-term toxicities against disease control. Given the patient's side effects and treatment duration, considering a switch to targeted therapies like dupilumab—which offer effective disease control with a different safety profile—may be appropriate SmPC Capsorin,NICE CG153.